

## AMENDMENTS TO THE ABSTRACT

Please replace the abstract as follows:

New lamellarins are provided of the general formula III ~~wherein X is selected from the group consisting of N, O and S; wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, R<sub>8</sub> and R<sub>9</sub> are each independently selected from the group consisting of H, OH, OR', SH, SR', SO<sub>2</sub>R', NHR', N(R')<sub>2</sub>, N=R', NHCOR', N(COR')<sub>2</sub>, NHSO<sub>2</sub>R', NO<sub>2</sub>, PO(R')<sub>2</sub>, PO(R')<sub>2</sub>, PO<sub>2</sub>R', C(=O)H, C(=O)R', CO<sub>2</sub>H, CO<sub>2</sub>R', OPO(R')<sub>2</sub>, OPO<sub>2</sub>R', OC(=O)H, OC(=O)R', N=C(R')<sub>2</sub>, substituted or unsubstituted C<sub>1</sub>-C<sub>12</sub> alkyl, substituted or unsubstituted C<sub>1</sub>-C<sub>12</sub> haloalkyl, substituted or unsubstituted C<sub>2</sub>-C<sub>12</sub> alkenyl, substituted or unsubstituted C<sub>2</sub>-C<sub>12</sub> alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl and substituted or unsubstituted heteroaromatic; wherein each of the R' groups is independently selected from the group consisting of H, OH, NO<sub>2</sub>, NH<sub>2</sub>, SH, CN, halogen, -O, C(=O)H, C(=O)CH<sub>3</sub>, CO<sub>2</sub>H, C(=O)R', substituted or unsubstituted C<sub>1</sub>-C<sub>18</sub> alkyl, substituted or unsubstituted C<sub>2</sub>-C<sub>18</sub> alkenyl, substituted or unsubstituted C<sub>2</sub>-C<sub>18</sub> alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted C<sub>1</sub>-C<sub>18</sub> alkoxy, substituted or unsubstituted C<sub>1</sub>-C<sub>18</sub> aminoalkyl, substituted or unsubstituted C<sub>1</sub>-C<sub>18</sub> aminoacid, substituted or unsubstituted C<sub>1</sub>-C<sub>18</sub> thioalkyl, substituted or unsubstituted C<sub>1</sub>-C<sub>18</sub> alkylsulfinyl, substituted or unsubstituted C<sub>1</sub>-C<sub>18</sub> alkylsulfonyl; wherein the pairs of groups R<sub>1</sub> and R<sub>2</sub>, R<sub>2</sub> and R<sub>3</sub>, R<sub>3</sub> and R<sub>4</sub>, R<sub>3</sub> and R<sub>9</sub>, R<sub>4</sub> and R<sub>9</sub>, R<sub>9</sub> and R<sub>5</sub>, R<sub>9</sub> and R<sub>6</sub>, or R<sub>6</sub> and R<sub>7</sub>, R<sub>7</sub> and R<sub>8</sub> may be joined into a carbocyclic or heterocyclic ring system; and the dotted line represents an single or double bond; or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof.~~

